Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Azcuris Co. Ltd. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action involves 1 distinct examiner and 1 distinct art unit. This concentrated focus indicates a specific technical path for the company's current prosecution effort. By operating within 1 art unit, the company maintains a narrow procedural footprint at the patent office. This structure allows the legal team to focus their resources on the requirements of a specific technical group within the Biotechnology & Pharmaceuticals field.
HABTE, KAHSAY is the busiest examiner, with 1 pending office action. This 1 action represents the total number of pending office actions for the company. As the only examiner with a pending action, this individual's review constitutes the entirety of the company's current active prosecution. For the practitioner, understanding the specific preferences of HABTE, KAHSAY is the primary factor in the current prosecution strategy. The outcome of the 1 pending office action will be determined by the review and feedback provided by this identified examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 85.0% | +7.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18566048 | NOVEL OXAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES COMPRISING THE SAME | HABTE, KAHSAY | 63d |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18566048 | NOVEL OXAZOLE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES COMPRISING THE SAME | HABTE, KAHSAY | 1624 | §102§112 | Final Rejection | 63d | Pending | Nov 30, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial